Valuation: Syndax Pharmaceuticals, Inc.

Market Cap 2.02B 1.77B 1.63B 1.5B 2.83B 195B 2.89B 19.47B 7.66B 95.29B 7.59B 7.42B 328B P/E 2026 *
-13.6x
P/E 2027 * -42.4x
Enterprise Value 2.22B 1.94B 1.79B 1.65B 3.11B 213B 3.17B 21.36B 8.4B 105B 8.32B 8.14B 360B EV / Sales 2026 *
6.44x
EV / Sales 2027 * 4.23x
Free-Float
98.3%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Syndax Pharmaceuticals, Inc.

1 day+0.40%
1 week-3.43%
Current month+4.30%
1 month+20.00%
3 months-5.90%
6 months+11.11%
Current year+8.52%
1 week 22.24
Extreme 22.2428
24.41
1 month 18.94
Extreme 18.94
25.24
Current year 16.66
Extreme 16.66
25.59
1 year 9.38
Extreme 9.38
25.59
3 years 8.58
Extreme 8.58
25.59
5 years 8.58
Extreme 8.58
29.86
10 years 3.39
Extreme 3.39
29.86
Manager TitleAgeSince
Chief Executive Officer 55 2022-02-02
Chief Tech/Sci/R&D Officer 57 2013-10-31
Director of Finance/CFO 55 2022-06-12
Director TitleAgeSince
Chairman 68 2008-11-30
Director/Board Member 55 2019-07-03
Director/Board Member 65 2017-01-03
Date Insider Type Main position Quantity % Market Cap.
7/8/26 Fiscal year

Chief Executive Officer

97,125 0.1096%
6/12/26 Fiscal year

Chief Technology Officer

93,705 0.1057%
6/1/26 Sell

Chief Executive Officer

-6,847 0.0077%
Change 5-day change 1-year change 3-year change Capi.($)
+0.40%-3.43%+141.01%+5.41% 2.02B
-1.29%-3.11%-0.35%+3.09% 49.18B
+3.90%-0.39%+386.06%+593.85% 39.58B
-1.70%+4.46%+5.93%+60.25% 34.69B
-2.01%-0.76%+28.41%-8.01% 34.42B
+0.06%+0.34%+2.38%+34.38% 27.11B
+0.46%-3.49% - - 16.21B
-0.04%-0.09%+72.42%+115.55% 15.36B
+1.12%+1.91%+14.54%+19.16% 14.05B
0.00%+1.36%+18.43%-30.79% 13.02B
Average +0.09%-0.32%+74.31%+88.10% 24.56B
Weighted average by Cap. -0.05%-0.21%+79.99%+122.28%

Financials

2026 *2027 *
Net sales 344M 301M 278M 256M 482M 33.16B 493M 3.32B 1.31B 16.24B 1.29B 1.26B 55.91B 502M 439M 405M 373M 703M 48.33B 719M 4.84B 1.9B 23.67B 1.88B 1.84B 81.48B
Net income -149M -130M -120M -111M -209M -14.33B -213M -1.43B -564M -7.02B -559M -547M -24.17B -47.62M -41.62M -38.4M -35.4M -66.72M -4.59B -68.2M -459M -181M -2.25B -179M -175M -7.73B
Net Debt 196M 171M 158M 146M 275M 18.88B 281M 1.89B 743M 9.25B 736M 720M 31.83B 100M 87.5M 80.74M 74.42M 140M 9.64B 143M 965M 380M 4.72B 376M 368M 16.26B
Logo Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. It is focused on developing a pipeline of cancer therapies. Its product candidates include Revuforj and Niktimvo. It is developing Revuforj, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant AML. It is also exploring the use of Revuforj as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing Niktimvo, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.
Employees
298
Date Price Change Volume
26-07-17 $22.80 +0.40% 1,061,474
26-07-16 $22.71 -3.44% 1,597,273
26-07-15 $23.52 -2.53% 2,282,986
26-07-14 $24.13 +5.42% 2,081,837
26-07-13 $22.89 -3.05% 1,423,054
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
22.80USD
Average target price
39.00USD
Spread / Average Target
+71.05%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SNDX Stock